<DOC>
	<DOCNO>NCT01643746</DOCNO>
	<brief_summary>The primary goal trial compare prospectively stent open Supera ( IDEV Technologies ) versus reference stent ( LifeStent , Bard Medical ) use C-arm CT. A secondary goal correlate stent open stent patency document Doppler ultrasound one year post implantation .</brief_summary>
	<brief_title>Evaluation Luminal Expansion Following Stenting Femoro-popliteal Occlusive Disease</brief_title>
	<detailed_description />
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>Age ≥ 18 year Patient ( legally authorize representative ) must give write informed consent . Symptomatic peripheralartery disease moderate severe intermittent claudication failure medical treatment ( Rutherford stage 2,3 ) chronic critical limb ischemia pain patient rest ( Rutherford stage 4 ) chronic critical limb ischemia ischemic ulcer ( Rutherford stage 5 , 6 ) stenosis 70 percent occlusion ipsilateral superficial femoral artery and/or proximal popliteal artery targetlesion length ≥ 8 ≤ 20 cm least one patent ( le 50 percent stenosed ) tibioperoneal runoff vessel ( TASC A , B , C lesion ) 25 . Proximal popliteal artery define popliteal artery joint line . The distal portion lesion locate least 4 cm joint line distal end stent 2 cm joint line . ABI ≤ 0.9 rest . ToeBrachial Index ( TBI ) may use ABI inadequate . Lesion calcification percentage least 25 % base CTA evaluation ( within 6 month patient enrolment ) Acute critical limb ischemia Untreated inflow disease ipsilateral pelvic artery ( 50 percent stenosis occlusion ) . Renal failure , creatinine clearance &lt; 50 µmol /l Severe allergy iodine contrast Patients uncorrected bleed disorder patient receive anticoagulation antiplatelet aggregation therapy Lesions &lt; 8 &gt; 20 cm length Calcification volume le 25 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>